市場調査レポート

商品コード

放射性医薬品セラノスティクス市場の2028年までの予測-製品タイプ、放射性同位元素、線源、用途、適応症、エンドユーザー別と世界分析

Radiopharmaceutical Theranostics Market Forecast to 2028 - Global Analysis By Product Type, Radioisotope, Source, Application, Indication, and End User

出版日: 2023年03月27日 | 発行: The Insight Partners

| ページ情報: 英文 185 Pages | 納期: 即納可能

価格

PDF (Single User License)

USD 4,550 709,572円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Site License)

USD 6,550 1,021,472円

レポートPDFを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 8,550 1,333,372円

レポートPDFを企業内すべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.95円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

放射性医薬品セラノスティクス市場は、2022年の18億1,458万米ドルから2028年には34億4,197万米ドルに達すると予測され、2022年から2028年にかけて11.3%のCAGRで成長すると予測されています。がんの発生率の上昇や心血管障害の治療への応用の高まりは、市場を強化する主要な要因の一つです。しかし、放射性医薬品セラノスティックスの承認に関する規制上の課題が、放射性医薬品セラノスティックス市場の成長を妨げています。

放射性医薬品は、がんの診断と治療に重要です。123I、124I、または低活性131I-ヨウ化物による診断スキャンに続いて、高活性131I-ヨウ化物による治療が行われます。同様に、褐色細胞腫や神経芽細胞腫などのアドレナリン作動性腫瘍は、123 I-メタヨードベンジルグアニジンで画像化し、131 I-メタヨードベンジルグアニジンで治療することができます。骨シンチグラフィーは、前立腺がんから進行した痛みを伴う骨転移を持つ患者を選択するために使用することができます。これらの患者には、β粒子またはα粒子を放出する骨シンチグラフィーの治療が有効です。神経内分泌腫瘍の診断と治療のためのソマトスタチン受容体標的ペプチドは、それぞれ68Ga-DOTATATEと177Lu-DOTATATEといった薬剤で、最近確立したセラノスティックスの一つです。

がんは、世界の主要な死因の一つであり、2020年には約1,000万人、つまりほぼ6人に1人が死亡すると言われています。最も一般的ながんの種類は、乳房、肺、結腸、直腸、前立腺です。National Cancer Registry Program Report 2020によると、インドでは、男性がん患者は2020年に679,421人、2025年には約763,575人とさらに増加すると予測され、女性がん患者は2020年に712,758人、2025年には806,218人と推定されています。高齢になると、免疫力が低下し、がんのリスクに屈することが多くなります。貧弱な生活習慣、労働時間の延長、ストレスの増大、喫煙、飲酒、避妊具の使用、非婚化、母乳育児の減少などが乳がん発症の原因となっています。

米国がん協会の2023年版レポートによると、2023年に甲状腺がんの新規症例が～43,720人（男性12,540人、女性31,180人）記録されます。また、同年に甲状腺がんによる死亡が2,120人（男性970人、女性1,150人）発生することも明らかにされました。放射性医薬品のセラノスティクスは、がん治療において有望な可能性を秘めています。セラノスティックスとは、適切な放射性医薬品を利用した治療・診断技術の組み合わせのことです。例えば、放射性ヨウ素は分化型甲状腺がんの診断と治療において、よく知られたセラノスティックスの応用があります。乳がんへの応用には、いくつかの放射性医薬品が利用可能です。これらの組には、43／44Sc／47Sc、64Cu／67Cu、83Sr／89Sr、86Y／90Y、110In／111In、124I／131I、152Tb／161Tb、152Tb／149Tb、68Ga／177Lu、及び90Y／177Luがあります。123I/131Iは、甲状腺がんの治療前および治療後の評価に使用される高品質の単一光子放射型コンピュータ断層撮影（SPECT）/CTに使用されるセラノシス対のよく知られた例です。

悪性神経膠腫は致命的な腫瘍であり、治療の選択肢は限られています。89Zrおよび177Lu標識Lumi804-αCD11bは、神経膠腫の腫瘍関連ミエロイド細胞（TAMC）のモニタリングと減少、および免疫療法の成果の向上を目的とした有望なセラノスティック技術です。さらに、PETイメージングや標的放射性医薬品治療（TRT）のための放射性医薬品に、セラノスティックスが組み込まれています。Lu-177（177Lu-dotatate：Lutathera）またはGa-68（68Ga-dotatate：NetSpot）で放射性標識されたDOTA-オクトレオテート（dotatate）は、FDA（食品医薬品局）によって、標的放射性医薬品療法（TRT）とポジトロン放射断層撮影（PET）イメージング用に承認されています。このように、放射性医薬品セラノスチックのアプローチは、さまざまな種類のがんの診断と治療において前例のない価値を持ち、放射性医薬品セラノスチックの市場全体の成長を後押ししています。

製品タイプの洞察

放射性医薬品セラノスティクス市場は、製品タイプに基づき、陽電子放射断層撮影（PET）トレーサー、ベータエミッター、アルファエミッターに区分されます。2022年、陽電子放射断層撮影（PET）トレーサー部門は放射性医薬品セラノスティクス市場で最大の市場シェアを占め、予測期間（2022-2028年）に最も高いCAGRを記録すると予測されます。PETは、PET放射性医薬品の体内分布に関する定量的情報を提供するイメージング技術です。PETイメージングには、放射性核種製造用のサイクロトロン、自動化学装置、精製装置、PETカメラなど、高価な装置が必要です。PET画像は、循環器科、神経科、がん診断などの分野で使用されています。PETは、他の画像検査で明らかになる前に、病気の発症を早期に発見することができます。ガリウム68やフッ素18などの陽電子放出剤を使用したPETでは、より高い解像度を得ることができます。また、放射性銅は膜透過性が高く、酸化還元電位が低いため、既存の低酸素イメージング技術に代わる有望なトレーサーとして開発されています。Ga-PSMA-11の成功は、前立腺がんをイメージングするためのPSMAを標的としたPETトレーサーの開発にさらに拍車をかけました。さらに、放射性医薬品開発およびその応用において、セラノスチックスPETトレーサーの利用が進んでいます。セラノスチックスPETトレーサーは、非侵襲的な全身ナビゲーターとして、最も効果的な薬剤候補の選択、最適な投与量と投与経路の決定に役立つ可能性があります。このように、より高い分解能や活性の定量化などの利点が、PETトレーサーセグメントの放射性医薬品セラノスティクス市場を後押ししています。

放射性同位元素のインサイト

放射性同位元素に基づいて、放射性医薬品セラノスティクス市場は、ルテチウム（Lu）177、ガリウム-68、ヨウ素-131、ヨウ素-123、テクネチウム-99、イットリウム-90（Y-90）、銅（Cu）64、18F、銅（Cu）67、その他と区分されています。2022年、ルテチウム（Lu）177セグメントは放射性医薬品セラノスティクス市場で最大の市場シェアを占め、予測期間（2022-2028年）に12.3％の最高CAGRを記録すると予測されています。ルテチウム-177（177Lu）は、核医学の分野に新たに加わったものです。今後数年間で、最も広範囲に使用される治療用放射性核種の1つになる可能性を秘めています。がん治療用のLu-177 PSMA療法は、進行した前立腺がんの症例を治療するために採用されています。Lu-177オクトレオテート療法は、頭頸部がんや消化器腫瘍を含む神経内分泌腫瘍（NET）の治療に使用されます。ルテチウム療法（ルテチウム-177-DOTA-オクソドトレオチド）は、標的核種療法またはペプチド受容体放射性核種療法（PRRT）として確認されています。米国食品医薬品局（FDA）は、ペプチド受容体放射性核種治療（PRRT）用の177Lu標識DOTA-TATEを承認しています。

出典：インサイト

放射性医薬品セラノスティクス市場は、線源に基づき、サイクロトロンと原子炉に分けられます。2022年の放射性医薬品セラノスティクス市場では、サイクロトロン分野が大きな市場シェアを占めており、予測期間（2022-2028年）にはより高いCAGRを記録すると予測されています。サイクロトロンは、フッ素-18（18F）などのプロトンに富む放射性同位元素の製造に最も適しています。商業的に利用可能なサイクロトロンで製造された医療用放射性同位元素には、炭素-11、窒素-13、酸素-15、フッ素-18（18F）、銅-64、ガリウム-67、ヨウ素-123、およびタリウム-201があります。国際原子力機関（IAEA）の2023年報告書によると、サイクロトロンで最も頻繁に製造される放射性同位元素は半減期の短いもので、特にフッ素-18、炭素-11、酸素-15、窒素-13はポジトロン放射断層撮影（PET）などのイメージング技術向けです。サイクロトロンは、PETに使用される放射性医薬品の製造のほぼ95％を占めています。また、放射性核種は、がん、パーキンソン病、アルツハイマー病、不眠症など、生命を脅かすさまざまな病気の研究、診断、治療に主に使用されるため、サイクロトロンの需要は増加しています。さらに、PETやSPECTなどの医療用画像処理技術は、サイクロトロンで製造された放射性同位元素に依存しています。

アプリケーションの洞察

用途に基づき、放射性医薬品セラノスティクス市場は標的治療薬（Rx）とコンパニオン診断薬（CDx）に二分されます。2022年の放射性医薬品セラノスティクス市場では、標的治療薬（Rx）分野が大きな市場シェアを占めており、予測期間中はより高いCAGRを記録すると予想されます。標的治療薬は、がんなどの有害な臨床症状を治療するための有望な戦略として登場しました。例えば、放射線治療の一種である「放射性核種」は、体内に注入されたモノクローナル抗体のような細胞を標的とする分子を使用します。さらに、細胞標的分子ががん細胞の特定の標的分子に結合することで、標的となったがん細胞を死滅させ、正常な細胞への害を最小限に抑える仕組みになっています。標的治療薬は、前立腺がんやその他のがんの治療に使用されています。このことは、神経内分泌膵臓腫瘍のソマトスタチン受容体を標的とした次の事例でよく理解できます。

68GaはDOTATOC、DOTATATE、DOTANOCなどのソマトスタチン受容体イメージング用に開発されています。ソマトスタチン受容体標的療法は、177Lu-DOTATATE（27）および90Y-DOTATATE（28）を用いて、手術不能のpNETを切除可能にするネオアジュバント療法に利用することができます。90Yはβ線を発する放射性核種で、膵臓の巨大な腫瘍に最も適しています。さらに、177Lu-DOTATOCと213Bi-DOTATOCは、比較的高い生物学的効果を示し、膵臓腺がん細胞の生存率を低下させる効果的な役割を担っています。

適応症の見識

適応症に基づき、放射性医薬品セラノスティクス市場は腫瘍学、神経学、循環器学、その他に区分されます。2022年の放射性医薬品セラノスティクス市場では、オンコロジー分野が最大の市場シェアを占めており、予測期間（2022-2028年）に最も高いCAGRを記録すると予測されています。セラノスティックス法は、ナノ粒子を患者の体内に投与し、光線力学療法を用いるもので、個別化医療への道を切り開くものです。これらの方法は、食道がん、前立腺がん、乳がんの治療、光線性角化症、光線性口唇炎、ボーエン病、基底細胞上皮腫、黄斑変性症の治療に適用することができます。がん治療用の放射性医薬品は、主にβ線放出核種で標識されています。i-131、Lu-177、イットリウム-90（Y-90）などの放射性核種がこの目的で頻繁に使用されています。崩壊すると、放出されたベータ粒子はエネルギーを失いながら組織内を1～12mm移動し、細胞に細胞毒性ダメージを与えてアポトーシスを誘発します。あるいは、より最近では、アルファ線を放出する放射性核種、例えばAt-211やAc-225が治療用途に探索されています。セラノスティックスは、前立腺がんの治療において、臨床医と患者によって成功裏に使用されてきました。このように、腫瘍学におけるこれらの治療法や標的治療に対する強い臨床ニーズは、予測期間中も腫瘍学分野の市場を後押ししています。

エンドユーザー向けインサイト

エンドユーザーに基づき、放射性医薬品セラノスティクス市場は病院、診断画像センター、学術・研究機関、その他に区分されます。病院セグメントは、世界の放射性医薬品セラノスティクス市場の2022年に最大の市場シェアを占めています。しかし、学術・研究機関セグメントは予測期間（2022-2028年）に最も高いCAGRを記録すると予測されています。病院は、心臓動脈瘤、神経学的動脈瘤、腫瘍学的腫瘍、およびその他の同様の疾患を治療するために、技術的に高度なシステムを採用しています。さまざまな疾患の有病率の上昇と病院数の増加が、病院向け放射性医薬品セラノスティクス市場セグメントの成長に寄与しています。

調査対象範囲
洞察パートナーズ調査報告書ガイダンス
市場セグメンテーション
- 放射性医薬品セラノスティクスの世界市場- 製品タイプ別
- 放射性医薬品セラノスティクスの世界市場-放射性同位元素別
- 放射性医薬品セラノスティクスの世界市場-供給元別
- 放射性医薬品セラノスティクスの世界市場-用途別
- 放射性医薬品セラノスティックスの世界市場-適応症別
- 放射性医薬品セラノスティクスの世界市場-エンドユーザー別
- 放射性医薬品セラノスティックスの世界市場-地域別

第2章放射性医薬品セラノスティクス市場-Key Takeaways

第3章調査手法

カバレッジ
2次調査について
1次調査について

第4章放射性医薬品セラノスティクス市場- 市場情勢

PEST分析
- 北米PEST分析
- 欧州PEST分析
- アジア太平洋PEST分析
- 中南米PEST分析
- 中東・アフリカPEST分析
専門家の見解

第5章放射性医薬品セラノスティックス市場- 主要な市場力学

市場促進要因
- がん罹患率の上昇
- 循環器疾患治療への応用が進む
市場抑制要因
- 放射性医薬品セラノスティクスの承認に向けた規制上の課題
マーケットオポチュニティ
- 放射性医薬品の個別化治療のためのセラノスティック・デジタルツイン
今後の動向について
- 核医学における放射性医薬品セラノスチックス
影響度分析

第6章放射性医薬品セラノスティクス市場-世界分析

放射性医薬品セラノスティクスの世界市場収益と予測・分析
放射性医薬品セラノスティックスの世界市場、地域別予測・分析
主要プレイヤーのマーケットポジショニング
- GEヘルスケア・テクノロジー株式会社
- キュリウム

第7章放射性医薬品セラノスティクスの世界市場- 製品タイプ別収益と2028年までの予測

放射性医薬品セラノスティクスの世界市場、製品タイプ別2021年・2028年売上高シェア（%）

第8章放射性医薬品セラノスティックスの世界市場分析- 放射性同位元素別

放射性医薬品セラノスティクスの世界市場、放射性同位元素別2021年・2028年売上高シェア（%）

第9章放射性医薬品セラノスティックスの世界市場分析-ソース別

放射性医薬品セラノスティクスの世界市場、2021年・2028年ソース別収益シェア（%）

第10章放射性医薬品セラノスティックスの世界市場分析-アプリケーション別

放射性医薬品セラノスティクスの世界市場、2021年・2028年アプリケーション別収益シェア（%）

第11章放射性医薬品セラノスティックスの世界市場分析-適応症別

放射性医薬品セラノスティクスの世界市場、2021年・2028年適応症別売上高シェア（%）

第12章放射性医薬品セラノスティックスの世界市場分析-エンドユーザー別

放射性医薬品セラノスティクスの世界市場、エンドユーザー別2021年・2028年売上高シェア（%）

第13章放射性医薬品セラノスティクス市場-2028年までの収益と予測- 地域分析

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- その他欧州
アジア太平洋地域
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- その他アジア太平洋地域
中東・アフリカ地域
- サウジアラビア
- 南アフリカ
- UAE
- その他中東とアフリカ
中南米
- ブラジル
- アルゼンチン
- その他南米・中米

第14章 COVID-19パンデミックが放射性医薬品セラノスティックス市場に与える影響

北米
欧州
アジア太平洋地域
中東・アフリカ地域
中南米

第15章放射性医薬品セラノスティクス市場- 業界情勢

放射性医薬品セラノスティックス市場の成長戦略
インオーガニックな成長戦略
有機的成長戦略

第16章企業プロファイル

Bayer AG
GE HealthCare Technologies Inc
Curium
Lantheus Medical Imaging, Inc.
Telix Pharmaceuticals Ltd.
Cardinal Health Inc
Advanced Accelerator Applications S.A.
Jubilant Radiopharma
Theragnostics
NuView Life Sciences

第17章付録

洞察パートナーズについて
用語集

図表

List Of Tables

Table 1. North America Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 2. North America Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 4. North America Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 5. North America Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 6. North America Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 7. United States Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 8. United States Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 9. United States Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 10. United States Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 11. United States Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 12. United States Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 13. Canada Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 14. Canada Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 15. Canada Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 16. Canada Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 17. Canada Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 18. Canada Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 19. Mexico Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 20. Mexico Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 21. Mexico Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 22. Mexico Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 23. Mexico Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 24. Mexico Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 25. Europe Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 26. Europe Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 27. Europe Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 28. Europe Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 29. Europe Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 30. Europe Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 31. Germany Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 32. Germany Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 33. Germany Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 34. Germany Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 35. Germany Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 36. Germany Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 37. United Kingdom Radiopharmaceutical Theranostics Market, by Product type - Revenue and Forecast to 2028 (US$ Million)
Table 38. United Kingdom Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 39. United Kingdom Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 40. United Kingdom Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 41. United Kingdom Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 42. United Kingdom Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 43. France Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 44. France Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 45. France Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 46. France Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 47. France Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 48. France Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 49. Italy Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 50. Italy Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 51. Italy Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 52. Italy Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 53. Italy Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 54. Italy Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 55. Spain Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 56. Spain Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 57. Spain Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 58. Spain Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 59. Spain Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 60. Spain Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 61. Rest of Europe Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 62. Rest of Europe Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 63. Rest of Europe Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 64. Rest of Europe Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 65. Rest of Europe Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 66. Rest of Europe Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 67. Asia Pacific Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 68. Asia Pacific Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 69. Asia Pacific Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 70. Asia Pacific Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 71. Asia Pacific Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 72. Asia Pacific Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 73. China Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 74. China Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 75. China Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 76. China Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 77. China Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 78. China Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 79. Japan Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 80. Japan Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 81. Japan Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 82. Japan Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 83. Japan Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 84. Japan Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 85. India Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 86. India Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 87. India Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 88. India Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 89. India Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 90. India Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 91. South Korea Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 92. South Korea Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 93. South Korea Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 94. South Korea Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 95. South Korea Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 96. South Korea Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 97. Australia Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 98. Australia Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 99. Australia Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 100. Australia Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 101. Australia Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 102. Australia Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 103. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 104. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 105. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 106. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 107. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 108. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 109. Middle East & Africa Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 110. Middle East & Africa Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 111. Middle East & Africa Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 112. Middle East & Africa Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 113. Middle East & Africa Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 114. Middle East & Africa Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 115. Saudi Arabia Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 116. Saudi Arabia Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 117. Saudi Arabia Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 118. Saudi Arabia Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 119. Saudi Arabia Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 120. Saudi Arabia Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 121. South Africa Radiopharmaceutical Theranostics Market, by Product type - Revenue and Forecast to 2028 (US$ Million)
Table 122. South Africa Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 123. South Africa Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 124. South Africa Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 125. South Africa Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 126. South Africa Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 127. UAE Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 128. UAE Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 129. UAE Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 130. UAE Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 131. UAE Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 132. UAE Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 133. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 134. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 135. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 136. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 137. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 138. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 139. South & Central America Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 140. South & Central America Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 141. South & Central America Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 142. South & Central America Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 143. South & Central America Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 144. South & Central America Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 145. Brazil Radiopharmaceutical Theranostics Market, by Product type - Revenue and Forecast to 2028 (US$ Million)
Table 146. Brazil Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 147. Brazil Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 148. Brazil Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 149. Brazil Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 150. Brazil Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 151. Argentina Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 152. Argentina Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 153. Argentina Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 154. Argentina Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 155. Argentina Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 156. Argentina Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 157. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 158. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 159. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 160. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 161. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 162. Rest of South & Central America Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 163. Recent Inorganic Growth Strategies in the Radiopharmaceutical Theranostics Market
Table 164. Recent Organic Growth Strategies in the Radiopharmaceutical Theranostics Market
Table 165. Glossary of Terms

List Of Figures

Figure 1. Radiopharmaceutical Theranostics Market Segmentation
Figure 2. Radiopharmaceutical Theranostics Market, by Region
Figure 3. Global Radiopharmaceutical Theranostics Market Overview
Figure 4. Positron Emission Tomography (PET) Tracers Segment Held Largest Share of Product Type Segment in Radiopharmaceutical Theranostics Market
Figure 5. Asia Pacific Expected to Show Remarkable Growth During Forecast Period
Figure 6. Radiopharmaceutical Theranostics Market, by Geography (US$ Million)
Figure 7. Global Radiopharmaceutical Theranostics Market - Leading Country Markets (US$ Million)
Figure 8. Global Radiopharmaceutical Theranostics Market - Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. South & Central America: PEST Analysis
Figure 13. Middle East & Africa: PEST Analysis
Figure 14. Experts' Opinion
Figure 15. Radiopharmaceutical Theranostics Market: Impact Analysis of Drivers and Restraints
Figure 16. Global Radiopharmaceutical Theranostics Market - Revenue Forecast and Analysis - 2020-2028
Figure 17. Global Radiopharmaceutical Theranostics Market, by Geography - Forecast and Analysis (2021-2028)
Figure 18. Market Positioning of Key Players in Radiopharmaceutical Theranostics Market
Figure 19. Global Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
Figure 20. Positron Emission Tomography (PET) Tracers: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 21. Beta Emitters: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 22. Alpha Emitters: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 23. Global Radiopharmaceutical Theranostics Market, by Radioisotope, 2021 & 2028 (%)
Figure 24. Technetium-99: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 25. Gallium-68: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 26. Iodine-131: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 27. Iodine-123: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 28. Fluorine-18 (18F): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 29. Yttrium 90 (Y-90): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 30. Lutetium (LU) 177: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 31. Copper (CU) 67: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 32. Copper (CU) 64: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 34. Global Radiopharmaceutical Theranostics Market, by Source, 2021 & 2028 (%)
Figure 35. Nuclear Reactors: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 36. Cyclotrons: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 37. Global Radiopharmaceutical Theranostics Market, by Application, 2021 & 2028 (%)
Figure 38. Targeted Therapeutics (Rx): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 39. Companion Diagnostics (CDx): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 40. Global Radiopharmaceutical Theranostics Market, by Indication, 2021 & 2028 (%)
Figure 41. Oncology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 42. Neurology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 43. Cardiology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 44. Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 45. Global Radiopharmaceutical Theranostics Market, by End User, 2021 & 2028 (%)
Figure 46. Hospitals: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 47. Diagnostic Imaging Centers: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 48. Academic & Research Institutes: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 49. Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 50. North America: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 51. North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 52. North America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
Figure 53. United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 54. Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 55. Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 56. Europe: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 57. Europe Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 58. Europe: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
Figure 59. Germany Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 60. United Kingdom Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 61. France Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 62. Italy Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 63. Spain Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 64. Rest of Europe Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 65. Asia Pacific: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 66. Asia Pacific Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 67. China: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 68. Japan: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 69. India: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 70. South Korea: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 71. Australia: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 72. Rest of Asia Pacific: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 73. Middle East & Africa: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 74. Middle East & Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 75. Saudi Arabia Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 76. South Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 77. UAE Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 78. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 79. South & Central America: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 80. South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 81. South & Central America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
Figure 82. Brazil Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 83. Argentina Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 84. Rest of South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 85. Impact of COVID-19 Pandemic on North American Country Markets
Figure 86. Impact of COVID-19 Pandemic in European Country Markets
Figure 87. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
Figure 88. Impact of COVID-19 Pandemic in Middle East & Africa Country Markets
Figure 89. Impact of COVID-19 Pandemic on South & Central American Country Markets
Figure 90. Growth Strategies in the Radiopharmaceutical Theranostics Market

Product Code: TIPRE00024328

The radiopharmaceutical theranostics market is expected to reach US$ 3,441.97 million by 2028 from US$ 1,814.58 million in 2022; it is estimated to grow at a CAGR of 11.3% from 2022 to 2028. The rising incidence of cancer and rising application in treatment of cardiovascular disorder are among the key forces bolstering the market. However, regulatory challenges for the approval of radiopharmaceutical theranostics hinder the radiopharmaceutical theranostics market growth.

Radiopharmaceuticals are important in the diagnosis and therapy of cancer; a diagnostic scan with 123I, 124I, or low-activity 131I-iodide is followed by therapy with high-activity 131I-iodide. Similarly, adrenergic tumors such as pheochromocytoma and neuroblastoma can be imaged with 123 I-meta-iodobenzylguanidine and treated with 131 I-metaiodobenzylguanidine. Bone scintigraphy can be used to select patients with painful bone metastases that progressed from prostate cancer. They might benefit from treatment with beta- or alpha-particle-emitting bone-seeking agents, the newest and most successful of which is 223Ra radium chloride. Somatostatin receptor targeting peptides for diagnosing and treating neuroendocrine tumors with agents such as 68Ga-DOTATATE and 177Lu-DOTATATE, respectively, are among the recently established theranostics.

Cancer is one of the leading causes of death worldwide, responsible for almost 10 million deaths in 2020, or almost one in six. The most common types of cancer are breast, lung, colon, rectum, and prostate. According to National Cancer Registry Program Report 2020, in India, male cancer cases were estimated at 679,421 in 2020 and are expected to further increase to about 763,575 in 2025, while female cancer cases were estimated at 712,758 in 2020 and 806,218 in 2025. As people age, they become immunocompromised and often succumb to cancer risks. Poor lifestyles, longer working hours, increasingly stressful lives, smoking, alcohol consumption, contraceptive use, nulliparity, and reduced breastfeeding all contribute to breast cancer incidence.

According to the American Cancer Society's 2023 report, ~43,720 new cases of thyroid cancer (12,540 in men and 31,180 in women) are recorded in 2023. The report also revealed that 2,120 deaths occurred from thyroid cancer (970 in men and 1,150 in women) in the same year. Radiopharmaceutical theranostics have promising potential in cancer therapy. Theranostics is the combination of therapeutic and diagnostic techniques that utilize a suitable radiopharmaceutical agent. For example, radioiodine has a well-known theranostic application in diagnosing and treating differentiated thyroid cancer. Several radiopharmaceutical theranostic pairs are available for breast cancer applications. These pairs include 43/44Sc/47Sc, 64Cu/67Cu, 83Sr/89Sr, 86Y/90Y, 110In/111In, 124I/131I, 152Tb/161Tb, 152Tb/149Tb, 68Ga/177Lu, and 90Y/177Lu. 123I/131I is a well-known example of theranostic pair that is used in high-quality single-photon emission computerized tomography (SPECT)/CT for pre- and post-therapeutic assessment of thyroid cancer.

Malignant gliomas are deadly tumors with the availability of only a few therapeutic options. 89Zr- and 177Lu-labeled Lumi804-αCD11b is a promising theranostic technique intended for monitoring and reducing tumor-associated myeloid cells (TAMCs) in gliomas and improving immunotherapy outcomes. Further, theranostics are incorporated in radiometals for PET imaging and targeted radiopharmaceutical therapy (TRT). DOTA-octreotate (dotatate) radiolabeled with Lu-177 (177Lu-dotatate: Lutathera) or Ga-68 (68Ga-dotatate: NetSpot) are approved by the Food and Drug Administration (FDA) for targeted radiopharmaceutical therapy (TRT) and positron emission tomography (PET) imaging. Thus, a radiopharmaceutical theranostic approach has unprecedented value in diagnosing and treating different types of cancer, which fuels the overall radiopharmaceutical theranostics market growth.

Product Type Insights

Based on product type, the radiopharmaceutical theranostics market is segmented positron emission tomography (PET) tracers, beta emitters, and alpha emitters. In 2022, the positron emission tomography (PET) tracers segment held the largest market share in radiopharmaceutical theranostics market, and it is anticipated to register the highest CAGR during the forecast period (2022-2028). PET is an imaging technique that provides quantitative information on the distribution of PET radiopharmaceuticals in the body. PET imaging requires expensive equipment, which includes a cyclotron for radionuclide production, automated chemistry devices, purification instrumentation, and PET cameras. PET imaging is used in areas such as cardiology, neurology, and cancer diagnosis. PET may detect the early onset of disease before it is evident on other imaging tests. Better resolution can be achieved via PET using positron emitters, such as gallium-68 and fluorine-18. PET tracers featuring radioactive copper have also been developed as a promising alternative for existing hypoxia imaging techniques due to their high membrane permeability and low redox potential. The success of Ga-PSMA-11 further inspired the development of PSMA-targeting PET tracers for imaging prostate cancer. Additionally, theranostics PET tracers are progressively used in radiopharmaceutical drug development and its application. Theranostic PET tracers have the potential to serve as a noninvasive whole-body navigator, which helps select the most effective drug candidates, and determine optimal dosage and administration route. Thus, benefits such as higher resolution, and quantification of activity boost the radiopharmaceutical theranostics market for the PET tracers segment.

Radioisotope Insights

Based on radioisotope, the radiopharmaceutical theranostics market is segmented Lutetium (Lu) 177, Gallium-68, Iodine-131, Iodine-123, Technetium-99, Yttrium-90 (Y-90), Copper (Cu) 64, 18F, Copper (Cu) 67, and others. In 2022, the Lutetium (Lu) 177 segment held the largest market share in radiopharmaceutical theranostics market, and it is anticipated to register the highest CAGR of 12.3% during the forecast period (2022-2028). Lutetium-177 (177Lu) is the latest addition to the field of nuclear medicine. It has potential to become one of the most extensively used therapeutic radionuclides in the coming years. Lu-177 PSMA therapy for cancer theranostic is employed to treat advanced prostate cancer cases. Lu-177 octreotate therapy is used to treat neuroendocrine tumors (NETs), including head and neck cancers and gastrointestinal tumors. Lutetium therapy (lutetium-177-DOTA-oxodotreotide) has been identified as targeted radionuclide therapy or peptide receptor radionuclide therapy (PRRT). The US Food and Drug Administration (FDA) has approved 177Lu-labeled DOTA-TATE for peptide receptor radionuclide therapy (PRRT).

Source Insights

Based on source, the radiopharmaceutical theranostics market is divided into cyclotrons and nuclear reactors. In 2022, the cyclotrons segment held a larger market share in radiopharmaceutical theranostics market and is anticipated to register a higher CAGR during the forecast period (2022-2028). Cyclotrons are best suited for producing proton-rich radioisotopes such as Fluorine-18 (18F). Commercially available cyclotron-produced medical radioisotope involves Carbon-11, Nitrogen-13, Oxygen-15, Fluorine-18 (18F), Copper-64, Gallium-67, Iodine-123, and Thallium-201. According to the International Atomic Energy Agency (IAEA) 2023 report, the most frequent radioisotope produced through cyclotrons are those with short half-lives, particularly fluorine-18, carbon-11, oxygen-15, and nitrogen-13, intended for imaging techniques such as positron emission tomography (PET). Cyclotrons account for almost 95% of the production of radiopharmaceuticals used in PET. Additionally, the demand for cyclotrons is increasing as radionuclides are majorly used in research, diagnosis, and treatment of a range of life-threatening diseases such as cancer, Parkinson's, Alzheimer's, and insomnia. Further, medical imaging techniques such as PET and SPECT depend on cyclotron-produced radioisotopes.

Application Insights

Based on application, the radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and companion diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in radiopharmaceutical theranostics market in 2022, and it is expected to register a higher CAGR during the forecast period. Targeted therapeutics have emerged as a promising strategy for treating harmful clinical conditions, such as cancer. For example, "radionuclide," a type of radiation therapy, uses a cell-targeting molecule such as a monoclonal antibody injected into the body. Further, the cell-targeting molecule binds to a specific target molecule on cancer cells, subsequently killing the targeted cancer cells; the mechanism ensures minimum harm to normal cells. Targeted therapeutics are used for treating prostate cancer and other types of cancers. This is well understood by the following case of targeting somatostatin receptors in neuroendocrine pancreatic tumors.

68Ga has been developed for somatostatin receptor imaging such as DOTATOC, DOTATATE, and DOTANOC. A somatostatin-receptor targeted therapy can be utilized for neoadjuvant therapy that renders inoperable pNET resectable by utilizing 177Lu-DOTATATE (27) and 90Y-DOTATATE (28). 90Y is a beta-emitting radionuclide best suited for bulky pancreatic tumors. Additionally, 177Lu-DOTATOC and 213Bi-DOTATOC have revealed relatively high biological effectiveness, and they are effectively responsible for decreasing the survival of pancreatic adenocarcinoma cells.

Indication Insights

Based on indication, the radiopharmaceutical theranostics market is segmented oncology, neurology, cardiology, and others. The oncology segment held the largest market share in radiopharmaceutical theranostics market in 2022, and it is anticipated to register the highest CAGR during the forecast period (2022-2028). Theranostics methods involve administering nanoparticles into the patient's body and using photodynamic therapy, which paves the way for personalized medicine. These methods can be applied in the treatment of esophageal cancer, prostate cancer, and breast cancer, in the treatment of actinic keratosis, actinic cheilitis, Bowen's disease, basal cell epithelioma, and macular degeneration. Therapeutic radiopharmaceuticals for cancer treatment are predominantly labeled with beta-emitting radionuclides. The radionuclides I-131, Lu-177, and Yttrium-90 (Y-90) are frequently used for this purpose. Upon decay, the emitted beta-particles travel 1-12 mm through tissue while losing energy and causing cytotoxic damage to the cell to induce apoptosis. Alternatively, and more recently, alpha-emitting radionuclides, e.g., At-211 or Ac-225, have been explored for therapeutic applications. Theranostics has been successfully used by clinicians and patients in treating prostate cancer. Thus, the strong clinical need for these therapies and targeted treatments in oncology continue to fuel the market for the oncology segment during the forecast period.

End User Insights

Based on end user, the radiopharmaceutical theranostics market is segmented hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022 of global radiopharmaceutical theranostics market. However, academic and research institutes segment is anticipated to register the highest CAGR during the forecast period (2022-2028). Hospitals employ technologically advanced systems to treat cardiac aneurysms, neurology aneurysms, oncology tumors, and other similar conditions. The rising prevalence of various diseases and an increasing number of hospitals contribute to the growth of the radiopharmaceutical theranostics market for hospitals segment.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the smart hospital beds market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global smart hospital beds market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Global Radiopharmaceutical Theranostics Market - by Product Type
- 1.3.2 Global Radiopharmaceutical Theranostics Market - by Radioisotope
- 1.3.3 Global Radiopharmaceutical Theranostics Market - by Source
- 1.3.4 Global Radiopharmaceutical Theranostics Market - by Application
- 1.3.5 Global Radiopharmaceutical Theranostics Market - by Indication
- 1.3.6 Global Radiopharmaceutical Theranostics Market - by End User
- 1.3.7 Global Radiopharmaceutical Theranostics Market - by Geography

2. Radiopharmaceutical Theranostics Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Radiopharmaceutical Theranostics Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America PEST Analysis
- 4.2.2 Europe PEST Analysis
- 4.2.3 Asia Pacific PEST Analysis
- 4.2.4 South & Central America PEST Analysis
- 4.2.5 Middle East & Africa PEST Analysis
4.3 Expert's Opinion

5. Radiopharmaceutical Theranostics Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Incidence of Cancer
- 5.1.2 Rising Application in Treatment of Cardiovascular Disorders
5.2 Market Restraints
- 5.2.1 Regulatory Challenges for Approval of Radiopharmaceutical Theranostics
5.3 Market Opportunities
- 5.3.1 Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies
5.4 Future Trends
- 5.4.1 Radiopharmaceutical Theranostics in Nuclear Medicine
5.5 Impact Analysis

6. Radiopharmaceutical Theranostics Market - Global Analysis

6.1 Global Radiopharmaceutical Theranostics Market Revenue Forecast and Analysis
6.2 Global Radiopharmaceutical Theranostics Market, by Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
- 6.3.1 GE HealthCare Technologies Inc
- 6.3.2 Curium

7. Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Product Type

7.1 Overview
7.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
- 7.2.1 Positron Emission Tomography (PET) Tracers
  - 7.2.1.1 Overview
  - 7.2.1.2 Positron Emission Tomography (PET) Tracers: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.2.2 Beta Emitters
  - 7.2.2.1 Overview
  - 7.2.2.2 Beta Emitters: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.2.3 Alpha Emitters
  - 7.2.3.1 Overview
  - 7.2.3.2 Alpha Emitters: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

8. Global Radiopharmaceutical Theranostics Market Analysis - by Radioisotope

8.1 Overview
8.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Radioisotope 2021 & 2028 (%)
- 8.2.1 Technetium-99
  - 8.2.1.1 Overview
  - 8.2.1.2 Technetium-99: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.2 Gallium-68
  - 8.2.2.1 Overview
  - 8.2.2.2 Gallium-68: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.3 Iodine-131
  - 8.2.3.1 Overview
  - 8.2.3.2 Iodine-131: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.4 Iodine-123
  - 8.2.4.1 Overview
  - 8.2.4.2 Iodine-123: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.5 Fluorine-18 (18F)
  - 8.2.5.1 Overview
  - 8.2.5.2 Fluorine-18 (18F): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.6 Yttrium 90 (Y-90)
  - 8.2.6.1 Overview
  - 8.2.6.2 Yttrium 90 (Y-90): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.7 Lutetium (LU) 177
  - 8.2.7.1 Overview
  - 8.2.7.2 Lutetium (LU) 177: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.8 Copper (CU) 67
  - 8.2.8.1 Overview
  - 8.2.8.2 Copper (CU) 67: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.9 Copper (CU) 64
  - 8.2.9.1 Overview
  - 8.2.9.2 Copper (CU) 64: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.10 Others
  - 8.2.10.1 Overview
  - 8.2.10.2 Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

9. Global Radiopharmaceutical Theranostics Market Analysis - by Source

9.1 Overview
9.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Source 2021 & 2028 (%)
- 9.2.1 Nuclear Reactors
  - 9.2.1.1 Overview
  - 9.2.1.2 Nuclear Reactors: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 9.2.2 Cyclotrons
  - 9.2.2.1 Overview
  - 9.2.2.2 Cyclotrons: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

10. Global Radiopharmaceutical Theranostics Market Analysis - by Application

10.1 Overview
10.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Application 2021 & 2028 (%)
- 10.2.1 Targeted Therapeutic (Rx)
  - 10.2.1.1 Overview
  - 10.2.1.2 Targeted Therapeutics (Rx): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 10.2.2 Companion Diagnostic (CDx)
  - 10.2.2.1 Overview
  - 10.2.2.2 Companion Diagnostics (CDx): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

11. Global Radiopharmaceutical Theranostics Market Analysis - by Indication

11.1 Overview
11.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Indication 2021 & 2028 (%)
- 11.2.1 Oncology
  - 11.2.1.1 Overview
  - 11.2.1.2 Oncology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.2 Neurology
  - 11.2.2.1 Overview
  - 11.2.2.2 Neurology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.3 Cardiology
  - 11.2.3.1 Overview
  - 11.2.3.2 Cardiology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.4 Others
  - 11.2.4.1 Overview
  - 11.2.4.2 Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

12. Global Radiopharmaceutical Theranostics Market Analysis - by End User

12.1 Overview
12.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by End User 2021 & 2028 (%)
- 12.2.1 Hospitals
  - 12.2.1.1 Overview
  - 12.2.1.2 Hospitals: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.2 Diagnostic Imaging Centers
  - 12.2.2.1 Overview
  - 12.2.2.2 Diagnostic Imaging Centers: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.3 Academic & Research Institutes
  - 12.2.3.1 Overview
  - 12.2.3.2 Academic & Research Institutes: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.4 Others
  - 12.2.4.1 Overview
  - 12.2.4.2 Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

13. Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - Geographic Analysis

13.1 North America: Radiopharmaceutical Theranostics Market
- 13.1.1 Overview
- 13.1.2 North America: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.1.3 North America: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.1.4 North America: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.1.5 North America: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.1.6 North America: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.1.7 North America: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.1.8 North America: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.1.8.1 United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.1.1 Overview
    - 13.1.8.1.2 United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.1.3 United States Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.1.8.1.4 United States Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.8.1.5 United States Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.8.1.6 United States Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.8.1.7 United States Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.8.1.8 United States Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.1.8.2 Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.2.1 Overview
    - 13.1.8.2.2 Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.2.3 Canada Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.1.8.2.4 Canada Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.8.2.5 Canada Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.8.2.6 Canada Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.8.2.7 Canada Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.8.2.8 Canada Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.1.8.3 Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.3.1 Overview
    - 13.1.8.3.2 Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.3.3 Mexico Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.1.8.3.4 Mexico Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.8.3.5 Mexico Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.8.3.6 Mexico Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.8.3.7 Mexico Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.8.3.8 Mexico Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
13.2 Europe: Radiopharmaceutical Theranostics Market
- 13.2.1 Overview
- 13.2.2 Europe: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.2.3 Europe: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.2.4 Europe: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.2.5 Europe: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.2.6 Europe: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.2.7 Europe: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.2.8 Europe: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.2.9 Europe: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  - 13.2.9.1 Germany: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.1.1 Overview
    - 13.2.9.1.2 Germany Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.1.3 Germany Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.1.4 Germany Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.1.5 Germany Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.1.6 Germany Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.1.7 Germany Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.1.8 Germany Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.2 United Kingdom: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.2.1 Overview
    - 13.2.9.2.2 United Kingdom Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.2.3 United Kingdom Radiopharmaceutical Theranostics Market, by Product type, 2019-2028 (US$ Million)
    - 13.2.9.2.4 United Kingdom Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.2.5 United Kingdom Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.2.6 United Kingdom Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.2.7 United Kingdom Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.2.8 United Kingdom Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.3 France: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.3.1 Overview
    - 13.2.9.3.2 France Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.3.3 France Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.3.4 France Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.3.5 France Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.3.6 France Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.3.7 France Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.3.8 France Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.4 Italy: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.4.1 Overview
    - 13.2.9.4.2 Italy Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.4.3 Italy Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.4.4 Italy Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.4.5 Italy Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.4.6 Italy Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.4.7 Italy Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.4.8 Italy Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.5 Spain: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.5.1 Overview
    - 13.2.9.5.2 Spain Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.5.3 Spain Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.5.4 Spain Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.5.5 Spain Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.5.6 Spain Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.5.7 Spain Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.5.8 Spain Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.6 Rest of Europe: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.6.1 Overview
    - 13.2.9.6.2 Rest of Europe Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.6.3 Rest of Europe Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.6.4 Rest of Europe Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.6.5 Rest of Europe Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.6.6 Rest of Europe Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.6.7 Rest of Europe Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.6.8 Rest of Europe Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
13.3 Asia Pacific: Radiopharmaceutical Theranostics Market
- 13.3.1 Overview
- 13.3.2 Asia Pacific: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.3.3 Asia Pacific: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.3.4 Asia Pacific: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.3.5 Asia Pacific: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.3.6 Asia Pacific: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.3.7 Asia Pacific: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.3.8 Asia Pacific: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.3.9 Asia Pacific: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  - 13.3.9.1 China: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.1.1 Overview
    - 13.3.9.1.2 China: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.1.3 China Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.1.4 China Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.1.5 China Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.1.6 China Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.1.7 China Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.1.8 China Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.2 Japan: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.2.1 Overview
    - 13.3.9.2.2 Japan: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.2.3 Japan Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.2.4 Japan Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.2.5 Japan Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.2.6 Japan Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.2.7 Japan Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.2.8 Japan Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.3 India: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.3.1 Overview
    - 13.3.9.3.2 India: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.3.3 India Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.3.4 India Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.3.5 India Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.3.6 India Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.3.7 India Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.3.8 India Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.4 South Korea: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.4.1 Overview
    - 13.3.9.4.2 South Korea: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.4.3 South Korea Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.4.4 South Korea Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.4.5 South Korea Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.4.6 South Korea Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.4.7 South Korea Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.4.8 South Korea Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.5 Australia: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.5.1 Overview
    - 13.3.9.5.2 Australia: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.5.3 Australia Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.5.4 Australia Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.5.5 Australia Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.5.6 Australia Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.5.7 Australia Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.5.8 Australia Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.6 Rest of Asia Pacific: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.6.1 Overview
    - 13.3.9.6.2 Rest of Asia Pacific: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.6.3 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.6.4 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.6.5 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.6.6 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.6.7 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.6.8 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
13.4 Middle East & Africa Radiopharmaceutical Theranostics Market
- 13.4.1 Overview
- 13.4.2 Middle East & Africa: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.4.3 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.4.4 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.4.5 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.4.6 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.4.7 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.4.8 Middle East & Africa: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.4.9 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  - 13.4.9.1 Saudi Arabia: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.1.1 Overview
    - 13.4.9.1.2 Saudi Arabia Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.1.3 Saudi Arabia Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.4.9.1.4 Saudi Arabia Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.4.9.1.5 Saudi Arabia Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.4.9.1.6 Saudi Arabia Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.4.9.1.7 Saudi Arabia Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.4.9.1.8 Saudi Arabia Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.4.9.2 South Africa: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.2.1 Overview
    - 13.4.9.2.2 South Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.2.3 South Africa Radiopharmaceutical Theranostics Market, by Product type, 2019-2028 (US$ Million)
    - 13.4.9.2.4 South Africa Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.4.9.2.5 South Africa Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.4.9.2.6 South Africa Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.4.9.2.7 South Africa Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.4.9.2.8 South Africa Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.4.9.3 UAE: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.3.1 Overview
    - 13.4.9.3.2 UAE Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.3.3 UAE Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.4.9.3.4 UAE Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.4.9.3.5 UAE Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.4.9.3.6 UAE Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.4.9.3.7 UAE Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.4.9.3.8 UAE Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.4.9.4 Rest of Middle East & Africa: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.4.1 Overview
    - 13.4.9.4.2 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.4.3 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.4.9.4.4 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.4.9.4.5 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.4.9.4.6 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.4.9.4.7 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.4.9.4.8 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
13.5 South & Central America Radiopharmaceutical Theranostics Market
- 13.5.1 Overview
- 13.5.2 South & Central America: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.5.3 South & Central America: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.5.4 South & Central America: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.5.5 South & Central America: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.5.6 South & Central America: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.5.7 South & Central America: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.5.8 South & Central America: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.5.9 South & Central America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  - 13.5.9.1 Brazil: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.1.1 Overview
    - 13.5.9.1.2 Brazil Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.1.3 Brazil Radiopharmaceutical Theranostics Market, by Product type, 2019-2028 (US$ Million)
    - 13.5.9.1.4 Brazil Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.5.9.1.5 Brazil Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.5.9.1.6 Brazil Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.5.9.1.7 Brazil Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.5.9.1.8 Brazil Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.5.9.2 Argentina: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.2.1 Overview
    - 13.5.9.2.2 Argentina Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.2.3 Argentina Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.5.9.2.4 Argentina Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.5.9.2.5 Argentina Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.5.9.2.6 Argentina Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.5.9.2.7 Argentina Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.5.9.2.8 Argentina Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.5.9.3 Rest of South & Central America: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.3.1 Overview
    - 13.5.9.3.2 Rest of South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.3.3 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.5.9.3.4 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.5.9.3.5 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.5.9.3.6 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.5.9.3.7 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.5.9.3.8 Rest of South & Central America Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)

14. Impact Of COVID-19 Pandemic on Radiopharmaceutical Theranostics Market

14.1 North America: Impact Assessment of COVID-19 Pandemic
14.2 Europe: Impact Assessment of COVID-19 Pandemic
14.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
14.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
14.5 South & Central America: Impact Assessment of COVID-19 Pandemic

15. Radiopharmaceutical Theranostics Market - Industry Landscape

15.1 Overview
15.2 Growth Strategies in the Radiopharmaceutical Theranostics Market
15.3 Inorganic Growth Strategies
- 15.3.1 Overview
15.4 Organic Growth Strategies
- 15.4.1 Overview

16. Company Profiles

16.1 Bayer AG
- 16.1.1 Key Facts
- 16.1.2 Business Description
- 16.1.3 Products and Services
- 16.1.4 Financial Overview
- 16.1.5 SWOT Analysis
- 16.1.6 Key Developments
16.2 GE HealthCare Technologies Inc
- 16.2.1 Key Facts
- 16.2.2 Business Description
- 16.2.3 Products and Services
- 16.2.4 Financial Overview
- 16.2.5 SWOT Analysis
- 16.2.6 Key Developments
16.3 Curium
- 16.3.1 Key Facts
- 16.3.2 Business Description
- 16.3.3 Products and Services
- 16.3.4 Financial Overview
- 16.3.5 SWOT Analysis
- 16.3.6 Key Developments
16.4 Lantheus Medical Imaging, Inc.
- 16.4.1 Key Facts
- 16.4.2 Business Description
- 16.4.3 Products and Services
- 16.4.4 Financial Overview
- 16.4.5 SWOT Analysis
- 16.4.6 Key Developments
16.5 Telix Pharmaceuticals Ltd.
- 16.5.1 Key Facts
- 16.5.2 Business Description
- 16.5.3 Products and Services
- 16.5.4 Financial Overview
- 16.5.5 SWOT Analysis
- 16.5.6 Key Developments
16.6 Cardinal Health Inc
- 16.6.1 Key Facts
- 16.6.2 Business Description
- 16.6.3 Products and Services
- 16.6.4 Financial Overview
- 16.6.5 SWOT Analysis
- 16.6.6 Key Developments
16.7 Advanced Accelerator Applications S.A.
- 16.7.1 Key Facts
- 16.7.2 Business Description
- 16.7.3 Products and Services
- 16.7.4 Financial Overview
- 16.7.5 SWOT Analysis
- 16.7.6 Key Developments
16.8 Jubilant Radiopharma
- 16.8.1 Key Facts
- 16.8.2 Business Description
- 16.8.3 Products and Services
- 16.8.4 Financial Overview
- 16.8.5 SWOT Analysis
- 16.8.6 Key Developments
16.9 Theragnostics
- 16.9.1 Key Facts
- 16.9.2 Business Description
- 16.9.3 Products and Services
- 16.9.4 Financial Overview
- 16.9.5 SWOT Analysis
- 16.9.6 Key Developments
16.10 NuView Life Sciences
- 16.10.1 Key Facts
- 16.10.2 Business Description
- 16.10.3 Products and Services
- 16.10.4 Financial Overview
- 16.10.5 SWOT Analysis
- 16.10.6 Key Developments

17. Appendix

17.1 About The Insight Partners
17.2 Glossary of Terms

放射性医薬品セラノスティクス市場の2028年までの予測-製品タイプ、放射性同位元素、線源、用途、適応症、エンドユーザー別と世界分析

Radiopharmaceutical Theranostics Market Forecast to 2028 - Global Analysis By Product Type, Radioisotope, Source, Application, Indication, and End User

目次

第1章 イントロダクション

第2章 放射性医薬品セラノスティクス市場-Key Takeaways

第3章 調査手法

第4章 放射性医薬品セラノスティクス市場- 市場情勢

第5章 放射性医薬品セラノスティックス市場- 主要な市場力学

第6章 放射性医薬品セラノスティクス市場-世界分析

第7章 放射性医薬品セラノスティクスの世界市場- 製品タイプ別収益と2028年までの予測

第8章 放射性医薬品セラノスティックスの世界市場分析- 放射性同位元素別

第9章 放射性医薬品セラノスティックスの世界市場分析-ソース別

第10章 放射性医薬品セラノスティックスの世界市場分析-アプリケーション別

第11章 放射性医薬品セラノスティックスの世界市場分析-適応症別

第12章 放射性医薬品セラノスティックスの世界市場分析-エンドユーザー別

第13章 放射性医薬品セラノスティクス市場-2028年までの収益と予測- 地域分析